{"prompt": "['Statistical analysis', 'Safety run-in:', '(generality)', 'Listing of baseline patient characteristics, treatments and safety data will be provided to', 'IDMC (as well to ANSM) at the time of the analyses including dose of treatments, toxicities', 'and serious adverse events.', 'Phase II study:', 'Primary endpoint will be analysed on the modified intent-to-treat population (patients with at', 'least one dose of treatment). All the baseline characteristics will be described on the overall', 'population and by treatment arm. Description of toxicities and other baseline variables will', 'be done using usual statistics: for continuous variables: mean, standard deviation, median,', 'inter-quartile interval and range, and for categorical variables frequencies and percentages.', 'Survival analyses will be estimated using Kaplan-Meier method. A detailed Statistical', 'Analysis Plan will be written before the database lock.', 'Biological study', 'Only for randomized phase II:', '-', 'Blood (plasma) and tumor samples will be collected in all patients in order to allow', 'translational research projects (Centre de Ressource Biologique EPIGENETEC, UMR-S', '1147, Paris, France, Headed by Prof. Pierre Laurent-Puig) in order to identify predictive', 'biomarkers of treatment efficacy including at least (for more details see \"ancillary studies\"):', 'microsatellite instability (tumor DNA and immunohistochemistry), immune response', '(including PD-L1 and PD-L2) and immune score (immunohistochemistry), circulating tumor', 'DNA (baseline and kinetic), tumor mutation load and gastric molecular sub-groups.', '- Stool samples will be collected prospectively in all patients in order to allow analysis of', 'microbiota (16S rRNA to identification of bacteria composing the intestinal microbiota of', 'patients).', 'Number of patients', 'Safety Run-in phases : 11 patients ;', 'Randomized phase II study : 94 patients', 'Overall study (safety run-in and phase II) : 105 patients', 'Duration of inclusion', 'Theoretical rate of inclusion: 4 per month', 'and length of', 'Safety run-in: 5 expert centers selected', 'participation for each', 'Safety analysis of the first 11 patients included: - Q1 2019 to Q1 2020', 'patient', 'Phase II study:', 'Number of centers: 50 (around 30 active centers)', 'Theoretical start of inclusion: Q1 2020', 'Theoretical end of inclusion: Q1 2022', 'End of the trial (primary and secondary endpoint analysis): Q2 2023', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 12 de 123']['EXAMINATION AND FOLLOW-UP SCHEDULE', 'DURING TREATMENT', 'AFTER TREATMENT END', 'BEFORE TREATMENT', 'and in case of treatment stop without radiological progression', '(e.g. toxicity or patient refusal)', '(for radiological progression)', 'During the 14 days', 'preceding the start of', 'Before each course of treatment', 'Every 8 weeks (at each evaluation)', 'Every 2-3 months up to death', 'treatment', 'Clinical and biological informed consent', 'X', 'Biopsies or tumor block, fixed in paraffin', 'X**', 'CLINICAL EXAMINATION', 'Weight, height, body surface area, BP, pulse, temperature', 'X', 'X', 'X', 'ECOG Performance statut', 'X', 'X', 'X', 'Evaluation of toxicities NCI-CTC Version 4.0 (Appendix 8)', 'X', 'X (until 12 months after the end', 'X (and 30 days after end of treatment)', 'of treatment)', 'QLQ-C30 and STO-22 questionnaires (Appendix 3,4) p', 'X', 'X', 'BIOLOGICAL ASSESSMENT', 'Laboratory assessment', 'X***', 'X*****', 'X***', 'Hepatitis B,C and HIV test', 'X', 'Pregnancy test', 'X', 'X******', 'CAE and CA 19.9 markers', 'X', 'X', 'DPD status*', 'X****', 'PARACLINICAL REVIEWS', 'Brain\u00b9 and thoraco-abdominal-pelvic CT scan or MRI', 'X****', 'X*******', 'X', 'ECG', 'X****', 'Determination of MSI/MSS status or tumoral block available', 'X', 'BIOLOGICAL STUDY', 'Blood samples (2 tubes/sample) p', 'X', 'X********', 'Stools p', 'X (5 days before first', 'X (only at W8 - 5 days before the', 'course)', 'evaluation)', 'FUTURE LINES', 'Start and end dates of treatment and the type of treatment of the', 'X', 'subsequent lines will be completed in the CRF', 'p. phase II only items are indicated and highlighted in red', '*.', 'DPD deficiency assessment following INCa and HAS recommendations (Avis n\u00b0 2018.0053/AC/SEAP du 28 novembre 2018)', '** The investigator need to ensure that tumor tissues are available and sent after the patient randomization', 'CBC, platelets, liver panel (bilirubin (total and conjugated), ALT, AST, ALP, GGT, LDH), serum creatinine, creatinine clearance (MDRD - Appendix 5), TSH, blood protein, albumin, prealbumin, CRP, coagulation (PT, PTT),', 'serum electrolytes (sodium, potassium, calcium, magnesium), lipase, glucose, urea, urinalysis (urine strip - check of the protein level, if more than 2 crosses then check the proteinurea on 24h).', 'Within 3 weeks prior to randomization', 'CBC, platelets, urea, liver panel (bilirubin (total and conjugated), ALT, AST, ALP, GGT), bilirubin (total and conjugated), serum electrolytes (sodium, potassium, calcium, magnesium), serum creatinine, creatinine clearance', '(MDRD Appendix 5).', 'For women with childbearing potential a pregnancy test will be performed each month during the treatment duration', \"Use same technique in each imaging examination as that of the initial evaluation. Send an anonymized copy of images in CD-ROM format to FFCD, 7 bd Jeanne d'Arc, BP 87900, 21079 DIJON cedex (centralized\", 'review for the secondary end point and the ancillary study)', 'Blood sample at 4 weeks for ancillary studies', '1', 'Brain imaging is required only at baseline by CT-scan (or brain MRI if injected CT-scan contraindicated). Imaging of brain lesion(s) by CT-scan or MRI is required every 8 weeks during treatmentif present at baseline', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 13 de 123']\n\n###\n\n", "completion": "END"}